Postoperative Systemic Inflammatory Response, Complication Severity, and Survival Following Surgery for Colorectal Cancer by unknown
ORIGINAL ARTICLE – COLORECTAL CANCER
Postoperative Systemic Inflammatory Response, Complication
Severity, and Survival Following Surgery for Colorectal Cancer
Stephen T. McSorley, MBChB, David G. Watt, MBChB, Paul G. Horgan, PhD, and Donald C. McMillan, PhD
Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK
ABSTRACT
Background. This study examined the relationship
between the magnitude of the postoperative systemic
inflammatory response (SIR), the severity of complica-
tions, and long-term outcomes following surgery for
colorectal cancer.
Methods. Data were recorded prospectively for patients
undergoing potentially curative surgery for colorectal
cancer in a single centre between 2008 and 2013. The
magnitude of the SIR was measured using C-reactive
protein (CRP). Complications were classified by Clavien-
Dindo grade. The impact on disease specific and overall
survival was assessed using univariate and multivariate
Cox regression.
Results. Of 377 patients included, the majority were male
(55 %), older than age 65 years (68 %), with colonic
(63 %) and node-negative disease (66 %). A total of 138
patients (37 %) had a complication, of which 26 (6 %)
were Clavien-Dindo grade 3 or 4 severity. Complication
severity was significantly associated with the established
CRP thresholds of 150 mg/L on postoperative day (POD) 3
(p\ 0.001) and POD 4 (p\ 0.001). Median follow-up
was 42 months with disease-specific survival 86 % and
overall survival 78 %. On univariate analysis, complication
severity [hazard ratio (HR) 1.66, 95 % confidence interval
(CI) 1.13–2.43, p = 0.009], and POD 4 CRP[ 150 mg/L
(HR 2.53, 95 % CI 1.43–4.48, p = 0.001) were associated
with disease-specific survival. On multivariate survival
analysis, POD 4 CRP[ 150 mg/L (HR 2.00, 95 % CI
1.12–3.59, p = 0.020), but not complication severity, was
significantly associated with disease-specific survival
independent of TNM stage (HR 2.46, 95 % CI 1.52–4.12,
p\ 0.001).
Conclusions. The magnitude of the postoperative SIR,
evidenced by CRP, was significantly associated with long-
term outcomes following surgery for colorectal cancer,
independent of complications and stage.
Colorectal cancer is a significant burden of disease in
the developed world.1 Surgical resection continues to form
the cornerstone of management of this disease. However,
surgery is not without problems in terms of postoperative
morbidity and mortality.2 Furthermore, it has become clear
that postoperative complications following surgery for
colorectal cancer are not only associated with poor short-
term outcomes but also with poorer long-term outcomes.3–6
Postoperative complications have previously been
defined as ‘‘deviation from the normal postoperative
course.’’7 They have been classified by type, primarily as
infective or noninfective, or by severity using the Clavien-
Dindo scale.3,7–10 There is good evidence that the type of
complication, in particular infective complications, has a
significant negative impact on cancer-specific and overall
survival following surgery for colorectal cancer.11,12 Fewer
studies have examined the impact of complication severity
on long-term outcomes, although those that have reported
poorer disease-free and overall survival.13,14 Indeed, a
recent meta-analysis reported that severe complications
had a greater impact on long-term outcomes following
surgery for colorectal cancer.15
The magnitude of the systemic inflammatory response,
as evidenced by postoperative CRP thresholds of 190 mg/L
on postoperative day (POD) 2, 170 mg/L on POD 3, and
145 mg/L on POD 4, have been reported to be associated
with the development of infective complications.16–18
More recently, a comprehensive review suggested that
CRP concentrations above a threshold of 150 mg/L on
POD 3–5 should prompt investigation and or treatment of
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potential postoperative complications in colorectal sur-
gery.19 Two recent studies have examined the relationship
between the magnitude of the postoperative systemic
inflammatory response, as measured by CRP, and the
severity of complications following surgery for colorectal
cancer.20,21 Moreover, two recent studies in oesopha-
gogastric cancer have suggested that CRP concentrations in
the postoperative period are significantly associated with
survival independent of postoperative complications.22,23
To the authors knowledge, no study investigating the
interaction between the magnitude of the postoperative
systemic inflammatory response and complication severity,
and their impact on long-term outcomes has been per-
formed in colorectal cancer surgery.
Therefore, the purpose of the present study was to
examine the relationship between the magnitude of the
postoperative systemic inflammatory response and com-
plication severity and to determine which, if any, had the




This observational study included patients who under-
went elective, potentially curative surgery for
histologically confirmed colorectal cancer in a single centre
between March 2008 and May 2013. Patients with meta-
static disease who underwent palliative procedures or had
existing inflammatory conditions were excluded.
All patients received prophylactic antibiotics and venous
thromboprophylaxis prior to the induction of anaesthesia as
per hospital policy. All patients were cared for in line with
a unit standardised enhanced recovery after surgery
(ERAS) protocol, which included preoperative carbohy-
drate drinks, early mobilisation, and early enteral nutrition,
with the avoidance of routine peritoneal and/or nasogastric
drainage. On each POD, patients were clinically assessed
and had blood samples, including serum CRP, obtained as
standard until discharged. Further postoperative investiga-
tion and intervention was at the discretion of the patient’s
surgical team who were not blind to postoperative blood
results.
METHODS
All data were collected prospectively in a database,
anonymised, and subsequently analysed. Recorded infor-
mation included patient demographics, tumour site, TNM
stage (TNM, AJCC), surgical approach, whether adjuvant
or neoadjuvant treatment was given, whether the
presentation was elective or emergency, the presence of
complications, preoperative serum CRP, and albumin
measurements. Data regarding the nature, severity, and
management of complications was retrospectively cate-
gorised using the Clavien-Dindo scale.7 Any uncertainties
were addressed by review of electronic and/or physical
case notes. Date and cause of death were crosschecked with
the Registrar General (Scotland). Death records were
complete until June 30, 2015, which served as the censor
date. The study was approved by the West of Scotland
Research Ethics Committee, Glasgow.
Serum concentrations of CRP (mg/L) were measured
using an autoanalyzer (Architect; Abbot Diagnostics,
Maidenhead, UK) with a lower detectable limit of 0.2 mg/
L as was serum albumin (normal range 35–50 g/L). The
preoperative modified Glasgow Prognostic Score (mGPS)
was calculated from preoperative serum CRP and
albumin.24
Statistical Analysis
Categorical data regarding patient characteristics were
compared using the Chi square test and Chi square test for
linear association where appropriate. Patients who under-
went colonic resection were analysed as a subgroup due to
significant differences in postoperative complication rates
between those with colonic and rectal cancers. Those
patients who died within 30 days of surgery or during the
same admission (Clavien-Dindo grade 5 complications)
were excluded from survival analysis. Univariate and
multivariate survival data were analysed using Cox’s pro-
portional hazards model. Variables associated with disease-
specific or overall survival at a significance level of p\ 0.1
on univariate analysis were included in multivariate mod-
elling using backward conditional regression where a two-
sided p value\0.05 was considered statistically significant.
Disease-specific survival was defined as time from date of
surgery to date of cancer-specific death. Overall survival
was defined as time from date of surgery to date of death
from any cause. Statistical analyses were performed using
IBM SPSS version 22 for Windows (Chicago, IL).
RESULTS
Patients
A total of 377 patients were included having undergone
potentially curative surgery for colorectal cancer in the
absence of metastatic disease. The majority were male
(55 %), older than age 65 years (68 %), with colonic
(63 %) and node-negative disease (66 %). In total, 110
patients (29 %) had a laparoscopic resection, and the
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remainder had open surgery. Amongst the 138 patients
with rectal cancer, 65 (47 %) with locally advanced or
margin-threatening disease had neoadjuvant treatment, of
which 10 (15 %) were subsequently found to have had a
pathological complete response. Of all included patients,
29 % had adjuvant treatment following surgery.
Complications
Of 377 patients, 138 (37 %) experienced complications
(Table 1). Four patients (1 %) died within 30 days of
surgery or during the same admission. When classified
using the Clavien-Dindo scale, 108 (30 % of all patients)
were grade 1–2 (i.e., required minor intervention) and 26
(6 %) were grade 3–4 (i.e., necessitated major interven-
tion). When patient’s demographic, pathological, and
clinical characteristics were compared across complication
severity (Table 2), male gender (p\ 0.01), ASA grade
(p\ 0.05), smoking status (p\ 0.05), and rectal cancer
(p\ 0.05) were significantly associated with Clavien-
Dindo grade. There was a significant association between
complication severity and the proportion of patients
breaching the established CRP threshold of 150 mg/L on
POD 2 (p = 0.004), POD 3, and POD 4 (both p\ 0.001).
Follow-Up
After exclusion of postoperative mortality (4, 1 %),
death due to any cause occurred in 81 patients (22 %); 53
(14 %) were cancer-specific. The median follow-up for
patients alive at the time of their censoring was 46 (range
24–86) months.
Disease-Specific Survival
On univariate analysis (Table 3), age [hazard ratio (HR)
1.54, 95 % confidence interval (CI) 1.08–2.21, p = 0.018],
ASA grade (HR 1.69, 95 % CI 1.16–2.46, p = 0.007),
TNM stage (HR 2.50, 95 % CI 1.63–3.85, p\ 0.001),
mGPS (HR 1.67, 95 % CI 1.23–2.26, p = 0.001), breach-
ing the established CRP threshold of 150 mg/L on POD 3
(HR 1.84, 95 % CI 1.01–3.35, p = 0.047) and POD 4 (HR
2.53, 95 % CI 1.43–4.48, p = 0.001) and complication
severity (HR 1.66, 95 % CI 1.13–2.43, p = 0.009) were
associated with disease-specific survival and included in
multivariate analysis. On multivariate analysis (Table 3),
ASA grade (HR 1.52, 95 % CI 1.01–2.28, p = 0.044),
mGPS (HR 1.49, 95 % CI 1.08–2.07, p = 0.016), TNM
stage (HR 2.46, 95 % CI 1.52–3.96, p\ 0.001), and
breaching the established CRP threshold of 150 mg/L on
POD 4 (HR 2.00, 95 % CI 1.12–3.59, p = 0.020) remained
independently associated with poorer disease-specific sur-
vival. Breaching the established CRP threshold of 150 mg/
L on POD 3 was not included in multivariate analysis,
because it was directly associated with breaching the
established CRP thresholds of 150 mg/L on POD 4, which
had a greater statistical significance on univariate analysis.
TABLE 1 Postoperative complications by severity
Complication n %
No complication 239 63
Any complication 138 37
Complication type
Infective
All infective complications 94 25
SSI
Wound infection 43 11.5
Anastomotic leak 16 4



















Renal failure 4 1
Acute urinary retention 3 0.75
Gastrointestinal










SSI surgical site infection, RSI remote site infection, UTI urinary tract
infection, MI myocardial infarction, VTE venous thromboembolism,
CVA cerebrovascular accident
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Overall Survival
On univariate analysis (Table 3), age (HR 1.83, 95 % CI
1.36–2.48, p\ 0.001), ASA grade (HR 1.92, 95 % CI
1.41–2.61, p\ 0.001), mGPS (HR 1.52, 95 % CI 1.18–
1.96, p = 0.001), TNM stage (HR 1.70, 95 % CI 1.25–
2.31, p = 0.001), breaching the established CRP threshold
of 150 mg/L on POD 2 (HR 1.99, 95 % CI 1.22–3.26,
p = 0.006, POD 3 (HR 1.76, 95 % CI 1.08–2.85,
p = 0.022), and POD 4 (HR 2.02, 95 % CI 1.27–3.20,
p = 0.003), and adjuvant treatment (HR 0.64, 95 % CI
0.37–1.09, p = 0.098) were associated with overall sur-
vival and included in multivariate analysis. On multivariate
analysis (Table 3), ASA grade (HR 1.49, 95 % CI 1.05–
2.10, p = 0.024), TNM stage (HR 2.12, 95 % CI 1.45–
3.09, p\ 0.001), breaching the established CRP threshold
of 150 mg/L on POD 4 (HR 2.14, 95 % CI 1.34–3.41,
p = 0.001), and adjuvant treatment (HR 0.33, 95 % CI
0.17–0.64, p = 0.001) all remained independently associ-
ated with overall survival. Breaching the established CRP
threshold of 150 mg/L on POD 2 and 3 were not included
in multivariate analysis, because they were directly
associated with breaching the established CRP thresholds
of 150 mg/L on POD 4, which had a greater statistical
significance on univariate analysis.
Colonic Resection
When the subgroup of 239 patients who underwent
surgery for colonic cancer were considered, 79 (33 %)
experienced complications (Table 4). No patients died
within 30 days of surgery or during the same admission.
When classified using the Clavien-Dindo scale, 63 were
grade 1–2 and 16 were grade 3–4. When patient’s demo-
graphic, pathological, and clinical characteristics were
compared across complication severity (Table 3), only
smoking status (p = 0.047) was significantly associated.
There was a significant association between complication
severity and the proportion of patients breaching the
established CRP threshold of 150 mg/L on POD 2
(p = 0.032), POD 3 (p = 0.002), and POD 4 (p = 0.005).
On multivariate analysis (Table 5) mGPS (HR 1.81,
95 % CI 1.20–2.72, p = 0.005), TNM stage (HR 2.28,
95 % CI 1.23–4.21, p = 0.009), and breaching the
TABLE 2 Patient characteristics by severity of complication following surgery for colorectal cancer
Characteristic All Clavien-Dindo complication grade
0a 1–2b 3–4c 5d p
N (%) 377 (100) 239 (63) 108 (30) 26 (7) 4 (1) –
Age (\65/65–74/[74) 122/149/106 82/96/61 31/44/33 9/7/10 0/2/2 0.451
Sex (male/female) 208/169 116/123 74/34 15/11 3/1 0.005
BMI (\20/20–25/36–30/[30) 16/112/114/90 12/69/75/55 3/32/31/28/94 1/8/8/6 0/3/0/1 0.833
ASA (1/2/3/4) 48/169/145/14 36/112/83/7 9/45/48/6 3/11/12/0 0/1/2/1 0.014
Smoking (never/ex/current) 159/150/61 114/89/31 37/46/23 8/11/7 0/4/0 0.015
Preop mGPS (0/1/2) 284/37/56 180/23/36 82/9/17 18/5/3 4/0/0 0.636
Site (colon/rectum) 239/138 160/79 63/45 16/10 0/4 0.024
TNM stage (0/I/II/III) 10/80/159/128 8/54/101/76 1/20/43/44 0/5/14/7 1/1/1/1 0.120
Neoadjuvant treatment (no/yes) 299/65 191/40 84/19 21/5 3/1 0.970
Approach (open/laparoscopic) 266/110 162/77 83/24 18/8 3/1 0.323
Surgery[ 4 h (yes/no) 83/247 51/154 22/76 9/16 1/1 0.456
Stoma (yes/no) 115/262 65/174 39/69 8/18 1/1 0.087
POD 2 CRP[ 150 mg/L (yes/no) 205/162 114/117 72/35 16/9 3/1 0.004
POD 3 CRP[ 150 mg/L (yes/no) 187/169 100/124 67/38 19/5 1/2 \0.001
POD 4 CRP[ 150 mg/L (yes/no) 126/200 58/137 51/51 16/10 1/2 \0.001
Adjuvant treatment (no/yes) 269/108 171/68 73/35 21/5 4/0 0.323
mGPS preoperative modified Glasgow Prognostic score (0 = CRP\ 10 mg/L, 1 = CRP C 10 mg/L and albumin C 35 g/L,
2 = CRP C 10 mg/L and albumin\ 35 g/L)
POD postoperative day
a 0 = no complication
b 1–2 = complication requiring minor intervention
c 3–4 = complication requiring significant intervention
d 5 = death
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established CRP threshold of 150 mg/L on POD 4 (HR
2.42, 95 % CI 1.13–5.18, p = 0.023) were independently
associated with disease specific survival after surgery for
colonic cancer. ASA grade (HR 1.99, 95 % CI 1.28–3.10,
p = 0.002), mGPS (HR 1.53, 95 % CI 1.11–2.10,
p = 0.010), and breaching the established CRP threshold
of 150 mg/L on POD 4 (HR 2.32, 95 % CI 1.29–4.20,
p = 0.005) were independently associated with overall
survival after surgery for colonic cancer.
DISCUSSION
The results of the present study report a significant asso-
ciation between the magnitude of the postoperative systemic
inflammatory response and complication severity, using the
Clavien-Dindo grade, following surgery for colorectal
cancer. Furthermore, the magnitude of the postoperative
systemic inflammatory response, in particular CRP on POD
4, was significantly associated with disease-specific and
overall survival independent of postoperative complications.
These relationships remained in a subgroup of patients who
underwent colonic surgery. Therefore, the present results
would suggest that the relationship between postoperative
complication severity and poorer long-term survival is, at
least in part, dependent on the magnitude of the postoperative
systemic inflammatory response.
The results of the present study are consistent with
previous studies showing an association between male
gender, preoperative ASA grade, smoking status, and
complication severity following colorectal surgery.19,25,26
Moreover, with two recent studies reporting the association
between complication severity and the magnitude of the
TABLE 3 Impact of the severity of postoperative complications on survival following surgery for colorectal cancer, univariate and multivariate
survival analysis
Survival Variable Univariate HR (95 % CI) p Multivariate HR (95 % CI) p
DSS Age 1.54 (1.08–2.21) 0.018 – 0.225
Sex 0.77 (0.45–1.32) 0.344 – –
BMI 0.88 (0.62–1.23) 0.446 – –
ASA 1.69 (1.16–2.46) 0.007 1.52 (1.01–2.28) 0.044
Smoking 1.00 (0.69–1.46) 0.984 – –
mGPS 1.67 (1.23–2.26) 0.001 1.49 (1.08–2.07) 0.016
Rectal 1.00 (0.57–1.74) 0.998 – –
TNM stage 2.50 (1.63–3.85) \0.001 2.46 (1.52–3.96) \0.001
Neoadjuvant treatment 1.23 (0.63–2.39) 0.548 – –
POD 2 CRP[ 150 mg/L 1.62 (0.91–2.89) 0.101 – –
POD 3 CRP[ 150 mg/L 1.84 (1.01–3.35) 0.047 – –
POD 4 CRP[ 150 mg/L 2.53 (1.43–4.48) 0.001 2.00 (1.17–3.59) 0.020
Clavien-Dindo grade 1.66 (1.13–2.43) 0.009 1.51 (0.98–2.33) 0.061
Adjuvant treatment 0.78 (0.42–1.46) 0.432 – –
OS Age 1.83 (1.36–2.48) \0.001 1.35 (0.97–1.87) 0.074
Sex 1.06 (0.68–1.64) 0.799 – –
BMI 0.85 (0.65–1.12) 0.242 – –
ASA 1.92 (1.41–2.61) \0.001 1.49 (1.05–2.10) 0.024
Smoking 1.20 (0.89–1.61) 0.238 – –
mGPS 1.52 (1.18–1.96) 0.001 – 0.170
Rectal 0.78 (0.49–1.25) 0.308 – –
TNM stage 1.70 (1.25–2.31) 0.001 2.12 (1.45–3.41) \0.001
Neoadjuvant treatment 0.97 (0.54–1.73) 0.914 – –
POD 2 CRP[ 150 mg/L 1.99 (1.22–3.26) 0.006 – –
POD 3 CRP[ 150 mg/L 1.76 (1.08–2.85) 0.022 – –
POD 4 CRP[ 150 mg/L 2.02 (1.27–3.20) 0.003 2.14 (1.34–3.41) 0.001
Clavien-Dindo grade 1.30 (0.93–1.81) 0.127 – –
Adjuvant treatment 0.64 (0.37–1.09) 0.098 0.33 (0.17–0.64) 0.001
HR hazard ratio, CI confidence interval, DSS disease-specific survival, OS overall survival, mGPS modified Glasgow Prognostic score, POD
postoperative day
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postoperative systemic inflammatory response in patients
with colorectal cancer and also in patients undergoing
surgery for gastric and oesophageal cancer.20–23
A recent meta-analysis reported that complication type
and severity were independently associated with poorer
oncologic outcomes following colorectal surgery and liver
resection for colorectal cancer.15 However, the present
study is the first to include a measure of the magnitude of
the systemic inflammatory response together with the
severity of complication in survival analysis following
surgery for colorectal cancer. Although the relationship
between postoperative infective complications and poorer
survival in patients with colorectal cancer has been
extensively documented, complication severity using the
Clavien-Dindo scale provides a validated, objective
framework for the definition of such postoperative
complications.10
Taken together the implications of these results are
important. They would suggest that the mechanisms that
link the magnitude of the postoperative systemic inflam-
matory response, postoperative complications, and poorer
oncological outcomes are inflammatory in aetiology.27 In
previous work, it has been reported that the presence of
preoperative systemic inflammation, as measured by the
mGPS, but not postoperative complication, was associated
with poorer long-term outcomes following surgery for
colorectal cancer.8 However, the magnitude of the post-
operative systemic inflammatory response was not
considered. More recently, it is now recognised that the
magnitude of the systemic inflammatory response follow-
ing surgery for colorectal cancer is associated with the
extent of postoperative complications.17,18,20,21 The present
study shows that both the pre- and postoperative systemic
inflammatory responses are associated with oncologic
outcomes independent of tumour stage and postoperative
complications.
The exact mechanisms underlying these relationships
are unclear. However, the presence of an innate immune
driven systemic inflammatory response can suppress
cytotoxic immunity and may promote the development of
postoperative complications and tumour progression.28–30
If this were proven to be the case, it therefore would be
rational to consider the postoperative systemic inflamma-
tory response a target for therapeutic intervention. Clearly,
such therapeutic intervention also would test the above
hypothesis, because it would be anticipated that a reduction
in the postoperative systemic inflammatory response would
not only result in a reduction in the severity of postoper-
ative complications but also improve long-term outcomes,
not only in colorectal cancer surgery, but in surgery for all
TABLE 4 Patient characteristics by severity of complication following surgery for colonic cancer
Characteristic All Clavien-Dindo complication grade
0a 1–2b 3–4c 5d p
N (%) 239 160 63 16 0 –
Age (\65/65–74/[74) 66/88/85 48/59/53 14/24/25 4/5/7 0/0/0 0.724
Sex (male/female) 127/112 77/83 42/21 8/8 0/0/0 0.111
BMI (\20/20–25/36–30/[30) 11/64/68/60 9/41/50/38 1/19/12/19 1/4/6/3 0/0/0/0 0.430
ASA (1/2/3/4) 24/99/105/11 20/70/63/7 2/23/34/4 2/6/8/0 0/0/0/0 0.227
Smoking (never/ex/current) 103/91/40 79/54/23 20/30/12 4/7/5 0/0/0 0.047
Preop mGPS (0/1/2) 170/28/41 115/18/27 46/6/11 9/4/3 0/0/0 0.513
TNM stage (0/I/II/III) 0/50/112/77 0/33/73/54 0/14/29/20 0/3/10/3 0/0/0/0 0.734
Approach (open/laparoscopic) 83/156 57/103 20/43 6/10 0/0 0.836
Surgery[ 4 h (yes/no) 28/179 17/118 7/50 4/11 0/0 0.303
Stoma (yes/no) 14/158 7/113 6/37 1/8 0/0 0.277
POD 2 CRP[ 150 mg/L (yes/no) 129/105 78/78 43/19 8/8 0/0 0.032
POD 3 CRP[ 150 mg/L (yes/no) 121/105 69/81 41/20 11/4 0/0 0.002
POD 4 CRP[ 150 mg/L (yes/no) 81/117 41/84 31/26 9/7 0/0 0.005
Adjuvant treatment (no/yes) 69/170 48/112 18/45 3/13 0/0 0.638
mGPS preoperative modified Glasgow Prognostic score (0 = CRP\ 10 mg/L, 1 = CRP C 10 mg/L and albumin C 35 g/L,
2 = CRP C 10 mg/L and albumin\ 35 g/L)
POD postoperative day
a 0 = no complication
b 1–2 = complication requiring minor intervention
c 3–4 = complication requiring significant intervention
d 5 = death
Postoperative Systemic Inflammatory Response, Complication Severity, and Survival Following Surgery 2837
solid tumours. It remains to be determined whether the
modulation of the postoperative systemic inflammatory
response may reduce the frequency and/or severity of
postoperative complications or improve long-term out-
comes following surgery for colorectal cancer.
Therefore, it is of interest that several meta-analyses
investigating trials of preoperative corticosteroids in major
abdominal and gastrointestinal surgery have suggested a
reduction in both the magnitude of the postoperative sys-
temic inflammatory response and postoperative
complications.31–33 The long-term outcomes of these trials
however is less clear; two, small follow-up studies suggested
that preoperative corticosteroids had a potentially negative
oncologic impact.34,35 However, preoperative corticos-
teroids have been widely incorporated into perioperative
care guidelines for colorectal surgery due to their efficacy in
the reduction of rates of postoperative nausea and vomit-
ing.36 Other strategies might include the use of NSAIDs, H2
receptor antagonists, or statins in the perioperative period,
each of which have been suggested to attenuate the systemic
inflammatory response in patients with cancer.29,37 Addi-
tionally, laparoscopic surgery has been associated with a
reduction in the magnitude of the postoperative systemic
inflammatory response where technically appropriate.38
A main limitation of the present study was the relatively
short follow-up period. In addition, a relatively small
number of Clavien-Dindo grade 3–4 complications occur-
red. The significant difference in frequency of severe
complication between colonic and rectal resection led to
the separate analysis of patients undergoing colonic
resection. Nevertheless, comparative analysis showed
similar significant relationships with survival compared
with the whole cohort.
In summary, the results of the present study show that
the magnitude of the postoperative systemic inflammatory
response was associated with oncologic outcome following
surgery for colorectal cancer, independent of postoperative
complications, or disease stage.
TABLE 5 Impact of the severity of postoperative complications on survival following surgery for colonic cancer, univariate and multivariate
survival analysis
Survival Variable Univariate HR (95 % CI) p Multivariate HR (95 % CI) p
DSS Age 1.52 (0.96–2.41) 0.073 – 0.316
Sex 0.72 (0.37–1.44) 0.356 – –
BMI 0.69 (0.44–1.09) 0.109 – –
ASA 1.63 (1.00–2.67) 0.051 1.70 (0.99–2.93) 0.057
Smoking 0.94 (0.58–1.52) 0.792 – –
mGPS 1.95 (1.34–2.82) \0.001 1.81 (1.20–2.72) 0.005
TNM stage 2.27 (1.32–3.90) 0.003 2.28 (1.23–4.21) 0.009
POD 2 CRP[ 150 mg/L 1.69 (0.82–3.48) 0.157 – –
POD 3 CRP[ 150 mg/L 1.97 (0.89–4.36) 0.094 – –
POD 4 CRP[ 150 mg/L 2.78 (1.31–5.91) 0.008 2.42 (1.13–5.18) 0.023
Clavien-Dindo grade 1.34 (1.01–1.78) 0.043 – 0.164
Adjuvant treatment 0.77 (0.35–1.70) 0.516 – –
OS Age 1.78 (1.23–2.57) 0.002 1.43 (0.94–2.15) 0.092
Sex 1.04 (0.61–1.78) 0.873 – –
BMI 0.75 (0.53–1.06) 0.100 – –
ASA 1.98 (1.34–2.93) 0.001 1.99 (1.28–3.10) 0.002
Smoking 1.19 (0.83–1.70) 0.354 – –
TNM stage 1.53 (1.04–2.25) 0.030 – 0.114
mGPS 1.66 (1.23–2.23) 0.001 1.53 (1.11–2.10) 0.010
POD 2 CRP[ 150 mg/L 2.18 (1.20–3.96) 0.010 – –
POD 3 CRP[ 150 mg/L 1.88 (1.03–3.42) 0.040 – –
POD 4 CRP[ 150 mg/L 2.33 (1.31–4.17) 0.004 2.32 (1.29–4.20) 0.005
Clavien-Dindo grade 1.08 (0.84–1.39) 0.548 – –
Adjuvant treatment 0.67 (0.35–1.27) 0.205 – –
HR hazard ratio, CI confidence interval, DSS disease-specific survival, OS overall survival, mGPS modified Glasgow Prognostic score, POD
postoperative day
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